Search - tctmd.com

Displaying 641 - 660 of 3795

Sort: Relevancy | Date

Get With the Program: Patient-Oriented Outcomes Are Key

Presentation TCT 2022

Get With the Program: Patient-Oriented Outcomes Are Key

Presenter: Davide Capodanno

September 17, 2022

TCT 280: Combined Use of Hyperemic and Non-Hyperemic Pressure Ratios for Revascularization Decision-Making

Presentation TCT 2022

TCT 280: Combined Use of Hyperemic and Non-Hyperemic Pressure Ratios for Revascularization Decision-Making

Presenter: Coen Boerhout

September 17, 2022

Revascularization in LV Systolic Dysfunction: Revived or Dead?

Presentation TCT 2022

Revascularization in LV Systolic Dysfunction: Revived or Dead?

Presenter: Divaka Perera

September 17, 2022

Presentation TCT 2022

TCT 36: Complete revascularization versus culprit lesion only PCI in patients with diabetes mellitus and multivessel coronary artery disease: A subgroup analysis of the COMPLETE trial

Presenter: Zardasht Oqab

September 17, 2022

TCT 35: Effects of Complete Revascularization According to Age in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel: Insights from the COMPLETE Trial

Presentation TCT 2022

TCT 35: Effects of Complete Revascularization According to Age in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel: Insights from the COMPLETE Trial

Presenter: Kevin Bainey

September 17, 2022

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

News Conference News ESC 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

Yael L. Maxwell

September 06, 2022

September 2022 News Roundup

News Opinion CV Team Dispatch

September 2022 News Roundup

September 01, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

CMR, PET Similar for Identifying Coronary Disease After CTA: Dan-NICAD 2

News Conference News ESC 2022

CMR, PET Similar for Identifying Coronary Disease After CTA: Dan-NICAD 2

August 29, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

News Daily News

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

August 19, 2022

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

August 05, 2022

CABG Bests PCI in Patients With Good Physical, Mental Health: SYNTAXES

News Daily News

CABG Bests PCI in Patients With Good Physical, Mental Health: SYNTAXES

Michael O'Riordan

July 22, 2022

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

July 20, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.